Global medical device maker Becton, Dickinson and Company (BD) has received approval from the European regulatory authorities for its BD Saf-T-Intima Safety Integrated IV Catheter System, which can be used in subcutaneous infusion therapies.
Made with BD Vialon biomaterial, the system’s pre-attached extension line lessens the cost in assembly time and also the risk of contamination.
BD claimed that the increase in-dwell times reduces overall costs of the therapy used besides catheter materials.
The system’s shielding design includes a telescoping needle shield that covers the stylet when it is withdrawn from the catheter, reducing the chances of potential injuries and infection in clinicians.
In addition, the chances of catching infection by patients isreduced as the subcutaneous route does not interact with the main blood vessels.
Unlike steel wing needle alternatives, the system’s Vialon softening capabilities provide a more comfortable cannula experience to patients while eliminating kinking issues.
The system has been approved by the British Standards Institution.
Subcutaneous infusion is a widely used therapy for rehydration, post-operative pain management, palliative care and pediatric care cases.
Subcutaneous infusion provides the benefit of many subcutaneous sites, rather than the restricted intravenous sites, and improves patient comfort.
This therapy is considered to be clinically safe, cost-effective, and a less invasive option than the intravenous route, which may cause device related bacteraemia.
Image: BD Saf-T-Intima Safety Integrated IV Catheter System. Photo: courtesy of Becton, Dickinson and Company.